TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Plasma concentration of Fevipiprant by AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of Fevipiprant by AUCinf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of Fevipiprant by Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sonographic finding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of common mental disorders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Clinical Infection With COVID-19 Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma and urine polyphenol metabolite concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pro-angiogenic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical COPD Questionnaire (CCQ) Total Score Change From Baseline at Month 13
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of COPD Exacerbations Leading to Hospitalization, Per Patient
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Pressure Reactivity - Handgrip Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Leaking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental area under the curve of plasma glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes of haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Seizure cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Disease Control Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall mortality at day 28
Endpoint domain: Mortality/survival
Primary endpoint: Change of DC-STAMP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Infant immunization status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Infant well child care status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of confirmed pregnancy at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: Microscopic vein damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Microbiome Composition Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fertilization rate of human oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of the IKDC subjective score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: All-cause mortality or repeat hospitalisation with heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Metabolic Availability of lysine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Number of Monthly Migraine Headache Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Chronic Respiratory Disease Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 6-minute walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prostate-specific antigen (PSA) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relative frequencies of adjuvant hormonal treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of Anaplastic Lymphoma Kinase (ALK) Biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concordance (Agreement) Between Ventana and NGS ALK Result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Detection of genomic alterations in ctDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative notified malaria incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to first day of radiotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: % of patients with leaks after gastric surgery correctly identified by biomarkers (PCT and CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: % of patients without leaks after gastric surgery correctly identified by biomarkers (PCT and CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline in cognitive impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in caregiver stress and burden
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Incidence of adverse events related to QRH-882260 Heptapeptide administration
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Weight in Pounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 10 Point Likert Scale of Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Pain Scale (VAS-pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Subsequent Reinjection and Surgical Operation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean diurnal IOP reduction of greater than or equal to 20% at Month 12 vs baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-surgical scar appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Average Plasma Concentration (Cavg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and Severity of Grade 3 and Grade 4 Treatment-Emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative pain upon arrival at and discharge from the postanesthesia care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Remission Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oligomeric beta-amyloid 42 levels in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Foot Posture Index-6 components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Staheli's Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiological Hallux Valgus Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active maximum dorsiflexion of the first metatarsophalangeal joint on weight bearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titer (GMT) for JEV neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of stone clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Numeric Rating Scale (NRS) for Pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Objective response rate by RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density of the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Abnormal Physical Examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed serum concentration (Cmax) of CNTO 328
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration-time curve (AUC 0-84D) of CNTO 328
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of coronary and aortic valve calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patients Achieving Target Hemoglobin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: IGF-1 reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Patients With an Infusion Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in UTI rate at 6 months
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Renal Function as Measured With eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Physiological Blood Levels of Melatonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: surgical quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Patients With Each Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of JNJ-64140284
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Cerebrospinal Fluid (CSF) Concentration (Cmax) of JNJ-64140284
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Procedural, Serious and Device-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Objective Response (PR or CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Hemarthrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Opioid Consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-operative Patient Reported Pain Score on the Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: GMT rate of HI antibody for each strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Solicited adverse events following vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Unsolicited adverse events following vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: SCR rate of HI antibody for each strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of adverse reactions after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Specific anti-EBOV antibody responses to the Ebola Zaire vaccine (Ad5-EBOV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specific T cell immune responses to the Ebola Zaire vaccine (Ad5-EBOV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of solicited local and systemic reactogenicity adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety Laboratory Values (Serum Chemistry)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety Laboratory Values (Hematology)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Second pathogenic molecular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Scoliotic Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Second Scoliotic Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Tilt of the Pelvis Relative to the Horizon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Kyphotic Curve Th5-Th12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lordotic Curve L1-S1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Knowledge, attitude, and practice toward ergonomics
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean dose of ribavirin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalcy of food intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in objective total, light and moderate-to-vigorous physical activity (PA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported total, light and moderate-to-vigorous physical activity (PA)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete healing of NSAID-induced gastropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fugl-Meyer Assessment for Lower-Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC) from time 0 to the last quantifiable concentration (AUC[0-t])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Energy and Mood level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: double slope sign of ΔV̇O2/ΔWR-Increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ISGA score 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in egg quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: AUC from time 0 to the last data point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular Twist
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plaque thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque hardness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sensitivity and Specificity for Detection or Exclusion of Coronary Artery Disease (CAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in apoptosis of T cells, B cells and APC cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PK parameters of nusinersen (ISIS 396443): Maximum observed plasma drug concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum degree of non-hematological toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Wear Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of tablets dispensed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Identifiability and time stability of distribution volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MFM-20 responsiveness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Gene transfer expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Objective Response Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline MMSE total scores immediately after TBS intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline MMSE total scores 4 weeks after TBS intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline ADAS-Cog total scores immediately after TBS intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline ADAS-Cog total scores 4 weeks after TBS intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of daily low dose tadalafil in treatment of overactive bladder syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Anti-Glycoprotein E (Anti-gE) Antibody Concentrations Higher Than or Equal to (≥)18 Milli-international Units Per Milliliter (mIU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Vaccine Response for Anti-gE Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Potential Immune-Mediated Disorders (pIMDs)
Endpoint domain: Adverse events/effects
Primary endpoint: Hepatic encephalopathy incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful administration of naloxone device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Hemoglobin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accuracy of Peripheral Pulse Oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Arterial Co-oximeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibitor development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported symptom severity and functional status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Global Perceived Effect
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUC 0-last
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Unscheduled Face-to-face Physician Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Injury Occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: IKDC Knee Joint Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Superficial Vaginal Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of patients with residual lesions within 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients with recurrence at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of life (acute)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life (long-term)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: change from baseline Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change from baseline liver stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline homeostasis model assessment Insulin resistance HOMA IR scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects reaching ACR20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain function by PET-Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Medication usage frequency
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Cognitive Function From Baseline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Count of Participants With a Decline in Cognitive Domain Scores
Endpoint domain: Adverse events/effects
Primary endpoint: AUC of CK-MB for 72 hours post PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects With Daily Headache Who Have Continuous Headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sustained MRD negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall survival (OS) in overall population
Endpoint domain: Mortality/survival
Primary endpoint: Overall survival (OS) in oligometastatic subgroup
Endpoint domain: Mortality/survival
Primary endpoint: Sensitivity and specificity for drug resistance detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recruitment rate achieved
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Usable EORTC H&N35 scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PTSD Symptoms assessed by PCL-M score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression Symptoms assessed by Beck Depression Inventory-II
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevention of placental malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cardiac arrest survival
Endpoint domain: Mortality/survival
Primary endpoint: change in insulin resistance measured with homeostasis model assessment (HOMA IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes